Introduction
============

The high-oncogenic risk types of human papillomavirus (HPV) can induce tumorigenesis via the E6 and E7 viral oncoproteins. These oncoproteins can functionally inactivate the tumor suppressor proteins p53 and pRb, resulting in a loss of cell cycle regulation and immortalization of keratinocytes ([@ref-11]; [@ref-26]). HPV-associated cancers are well documented in cervical cancer, in which 99.7% of cases harbor a high-risk HPV type ([@ref-32]). At the end of the last century, an association between HPV and head and neck squamous cell carcinoma (HNSCC) was identified, with an overall prevalence of 25% of tumors harboring HPV ([@ref-13]; [@ref-24]; [@ref-16]). There is mounting evidence of a strong association between HPV and oropharyngeal squamous cell carcinoma (OPSCC), as documented in Europe and the United States ([@ref-1]). Currently, HPV-positive and HPV-negative OPSCCs are thought to be two distinct diseases.

Previously, we found that Taiwanese patients with oropharyngeal cancer had a lower prevalence of HPV than that of patients from Western populations ([@ref-6]; [@ref-2]). In Taiwan, betel nut chewing has a significant impact on health and may cause these differences. Betel nut chewing plays an important role in the development of upper aerodigestive tract malignancies, and synchronous or metachronous tumors of the upper aerodigestive tract are commonly observed in these patients ([@ref-30]). [@ref-18] also observed that betel nut chewing and tobacco have a synergistic effect on the development of LSCC.

The microenvironment of the laryngeal mucosa is similar to that of the uterine cervix, which has an epithelial junctional area between squamous and columnar epithelia; the junctional area is a potential site for HPV infection ([@ref-15]). Previous studies have found that low-risk HPV is associated with recurrent respiratory papillomatosis ([@ref-4]), while high-risk HPV is associated with laryngeal cancer ([@ref-7]; [@ref-22]; [@ref-25]). However, the association between laryngeal squamous cell carcinoma (LSCC) and HPV infection remains controversial due to inconsistent results ([@ref-17]; [@ref-31]; [@ref-34]). In a systemic review and meta-analysis, the attributable fractions of HPV infection in LSCC cases were 19.1% and 8.6% according to p16 and E6/E7 mRNA expression, respectively ([@ref-27]).

In addition, the relationship between HPV and LSCC has rarely been examined in a primary surgical cohort. Therefore, this study sought to clarify the role of HPV in LSCC and analyzed correlations among HPV, clinicopathological parameters, and clinical outcomes.

Materials and Methods
=====================

Patients and clinicopathological data
-------------------------------------

This retrospective study enrolled patients who underwent primary surgical resection with or without adjuvant radiotherapy or chemoradiotherapy between 2006 and 2009 at Chang Gung Memorial Hospital, Kaohsiung, Taiwan. Their clinicopathological characteristics were obtained from clinical records, including age, sex, T and N classification, TNM stage, tumor differentiation, histories of betel nut chewing, alcohol drinking, smoking, and survival. The TNM stage was classified according to the 2009 American Joint Committee on Cancer system as confirmed by the Head and Neck Oncology Group. This study was approved by the Medical Ethics and Human Clinical Trial Committees at Chang Gung Memorial Hospital (Ethical Application Ref: 101-3112B).

Detection of HPV
----------------

Paraffin-embedded samples from identified tumor blocks of each specimen were collected in 1.5-mL Eppendorf tubes for DNA extraction. The tumor blocks were cut after thorough cleaning of the microtome blades, and a blank paraffin section was cut as a control to prevent contamination. After the deparaffinizing procedure, genomic DNA was extracted using the QIAamp tissue kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. A total of 50 µL eluted DNA were obtained, of which 1 µL was used as the PCR template. A 192-bp HPV DNA fragment was amplified using MY11/GP6+ biotinylated consensus primers targeting the L1 region of HPV. The DNA integrity of samples was assessed by amplification of β-globin as an internal control. The pre- and post-PCR amplifications were performed in two independent rooms. The HPV-positive samples were all reconfirmed, and HPV-negative samples were randomly selected for repeat procedures to confirm the results. In the HPV-positive samples, HPV was genotyped using a commercial PCR-based reverse-blot assay (EasyChip HPV Blot; King Car, Yilan, Taiwan), which can detect 39 different HPV types. Finally, the HPV types were identified by visual assessment protocol according to the manufacturer's instructions ([@ref-14]; [@ref-21]).

Statistical analysis
--------------------

Fisher's exact test was used to evaluate the correlations between clinicopathological variables and HPV status. In all statistical analyses, *p*-values \< 0.05 and \< 0.1 were considered to indicate significance and marginal significance, respectively. Variables considered in the survival analysis included age, sex, T classification, N classification, TNM stage, tumor differentiation, tumor subsite, second primary cancer, adjuvant therapy, extranodal extension, and the presence of HPV in tumor cells. The Kaplan--Meier method was used for the survival analysis, and statistical significance was defined as *p* \< 0.05, as assessed using the log rank test.

Results
=======

A total of 106 patients (103 men, 3 women; mean age 61.1 ± 11.8 years) were enrolled in this study. Tumor subsites included supraglottic (*n* = 40), glottic (*n* = 54), transglottic (*n* = 11), and subglottic (*n* = 1) cancers. [Table 1](#table-1){ref-type="table"} summarizes the clinicopathological characteristics. The incidence of a second primary cancer (synchronous or metachronous) was 17.0% (*n* = 18), including esophageal carcinoma in six (5.7%) patients, lung cancer in four (3.8%), other head and neck cancer subsites in six (5.7%), thyroid cancer in one (0.9%), and leukemia in one (0.9%). The second primary head and neck cancers were oral cancer in three, tonsillar cancer in two, and soft palate cancer in one patient.
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###### Table of clinicopathological features in different HPV status.

Correlation between the clinicopathological features and HPV status.

![](peerj-05-3395-g003)

  Variables               No.   HPV (−)   HPV (+)   *p* value
  ----------------------- ----- --------- --------- -------------------------------------------
  Gender                                            
  Male                    103   89        14        1.000
  Female                  3     3         0         
  Age                                               
  \<60 y/o                52    49        3         0.042[^\*^](#table-1fn2){ref-type="fn"}
  ≥60 y/o                 54    43        11        
  T classification                                  
  T1 and T2               74    64        10        1.000
  T3 and T4a              32    28        4         
  N classification                                  
  Positive                28    25        3         0.756
  Negative                78    67        11        
  TNM stage                                         
  Stage I and II          62    54        8         1.000
  Stage III and IV        44    38        6         
  Extranodal extension                              
  Positive                16    15        1         0.560
  Negative                12    10        2         
  Adjuvant RT/CCRT                                  
  Yes                     27    24        3         1.000
  No                      79    68        11        
  Tumor recurrence                                  
  Yes                     23    23        0         0.037[^\*^](#table-1fn2){ref-type="fn"}
  No                      83    69        14        
  Second primary cancer                             
  Yes                     18    15        3         0.703
  No                      88    77        11        
  Tumor differentiation                             
  Well                    28    25        3         0.756
  Moderate and poor       78    67        11        
  Tumor subsites                                    
  Transglottic            11    11        0         0.117
  Glottic                 54    47        7         
  Supraglottic            40    34        6         
  Subglottic              1     0         1         
  Tobacco use                                       
  Smoking                 93    83        10        0.068[^\*\*^](#table-1fn3){ref-type="fn"}
  Non-smoking             13    9         4         
  Alcohol use                                       
  Drinking                51    47        4         0.154
  Non-drinking            55    45        10        
  Betel nut chewing                                 
  Chewing                 53    46        7         1.000
  Non-chewing             53    46        7         

**Notes.**

RTradiotherapyCCRTconcurrent chemoradiotherapy

Statistical significance.

Marginal significance.

HPV genotyping
--------------

HPV was detected in 14 patients (13.2%): 11 (78.6%) specimens were positive for HPV-16, one (7.1%) for HPV-18, one (7.1%) for HPV-58, and one (7.1%) for both HPV-16 and -58 ([Fig. 1A](#fig-1){ref-type="fig"}). HPV was present in the glottic, supraglottic, and subglottic laryngeal subsites in seven (50%), six (42.9%), and one (7.1%) patients, respectively ([Fig. 1B](#fig-1){ref-type="fig"}).

![The distributions of different HPV types.\
The distributions of (A) various HPV types in laryngeal cancer and (B) HPV at different laryngeal subsites.](peerj-05-3395-g001){#fig-1}

Clinicopathological parameters
------------------------------

The patients with HPV-positive tumors were significantly older (*p* = 0.042) and had a higher local/regional control rate (*p* = 0.037) than that of patients with HPV-negative tumors. Fewer patients with HPV-positive tumors were smokers, although this had marginal significance (*p* = 0.068; [Table 1](#table-1){ref-type="table"}).
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###### Table of outcome according to different clinicopathological features.

Actuarial 5-year overall survival, disease-specific survival and local/regional control rate according to the clinicopathological features.
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  Variable                No    OS     *p*-value                                  DSS    *p*-value                                    Recurrence- free   *p*-value
  ----------------------- ----- ------ ------------------------------------------ ------ -------------------------------------------- ------------------ ------------------------------------------
  HPV status                                                                                                                                             
  Positive                14    64.3   0.8056                                     100    0.1485                                       100                0.0494[^\*^](#table-2fn2){ref-type="fn"}
  Negative                92    67.4                                              84.8                                                75.0               
  Gender                                                                                                                                                 
  Male                    103   67.0   0.9186                                     87.4   0.3010                                       79.6               0.0490[^\*^](#table-2fn2){ref-type="fn"}
  Female                  3     66.7                                              66.7                                                33.3               
  Age                                                                                                                                                    
  \<60 y/o                52    76.9   0.0416[^\*^](#table-2fn2){ref-type="fn"}   86.5   0.9345                                       78.9               0.8140
  ≥60 y/o                 54    57.4                                              87.0                                                77.8               
  Tumor differentiation                                                                                                                                  
  Well                    28    78.6   0.1416                                     96.4   0.0818                                       78.6               0.9210
  Moderate/poor           78    62.8                                              83.3                                                78.2               
  Tumor site                                                                                                                                             
  Glottic                 54    81.5   0.0011[^\*^](#table-2fn2){ref-type="fn"}   96.3   0.0021[^\*^](#table-2fn2){ref-type="fn"}     81.5               0.2499
  Non-Glottic             52    51.9                                              76.9                                                75.0               
  ENE                                                                                                                                                    
  Yes                     16    37.5   0.1563                                     56.3   0.1177                                       68.8               0.1230
  No                      12    66.7                                              83.3                                                91.7               
  T classification                                                                                                                                       
  T1 and T2               74    70.3   0.1762                                     90.5   0.0589[^\*\*^](#table-2fn3){ref-type="fn"}   79.7               0.4137
  T3 and T4a              32    59.4                                              78.1                                                75.0               
  N classification                                                                                                                                       
  Negative                78    73.1   0.0161[^\*^](#table-2fn2){ref-type="fn"}   93.6   0.0003[^\*^](#table-2fn2){ref-type="fn"}     78.2               0.9535
  Positive                28    50.0                                              67.9                                                78.6               
  TNM stage                                                                                                                                              
  I, II                   62    72.6   0.1044                                     95.2   0.0021[^\*^](#table-2fn2){ref-type="fn"}     80.7               0.3744
  III, IVa                44    59.1                                              75.0                                                75.0               
  Second primary cancer                                                                                                                                  
  Yes                     18    44.4   0.0338[^\*^](#table-2fn2){ref-type="fn"}   100    0.1059                                       88.9               0.3066
  No                      88    71.6                                              84.1                                                76.1               
  Adjuvant RT/CCRT                                                                                                                                       
  Yes                     27    63.0   0.5087                                     81.5                                                88.9               0.1271
  No                      79    68.4                                              88.6   0.3121                                       74.7               

**Notes.**

ENEextranodal extension of lymph nodeRTRadiotherapyCCRTConcurrent chemoradiotherapy

Statistical significance.

Marginal significance.

Survival analysis
-----------------

In this cohort, the 5-year overall (OS) and disease-specific (DSS) survival rates were 67.0% and 86.8%, respectively. The median follow-up period was 82.7 (range 6.0--127.4) months. Twenty-one patients died of diseases other than laryngeal cancer, in most cases chronic obstructive pulmonary disease (COPD), lung cancer, or esophageal cancer. The 5-year OS was significantly poorer in patients who were older (*p* = 0.0416), had a positive N classification (*p* = 0.0161), had a second primary cancer (*p* = 0.0338), and had non-glottic cancer (*p* = 0.0011). The 5-year DSS was significantly poorer in patients with a positive N classification (*p* = 0.0003), advanced TNM stage (*p* = 0.0021), and non-glottic cancer (*p* = 0.0021) ([Table 2](#table-2){ref-type="table"}). There was no significant difference in the 5-year OS between HPV-positive and -negative tumors ([Fig. 2A](#fig-2){ref-type="fig"}). The patients with HPV-positive tumors had a better 5-year DSS (100% *vs*. 84.8%, *p* = 0.1485), although the difference did not reach statistical significance ([Fig. 2B](#fig-2){ref-type="fig"}). However, the 5-year local/regional control rate was significantly better in HPV- positive tumors than in HPV-negative tumors (100% *vs*. 75%, *p* = 0.0494; [Fig. 2C](#fig-2){ref-type="fig"}).

![Clinical outcome in HPV-positive and HPV-negative tumors.\
The effect of HPV status on (A) overall survival, (B) disease-specific survival, and (C) local/regional control rates.](peerj-05-3395-g002){#fig-2}

Discussion
==========

Smoking and drinking are the main risk factors for head and neck cancer. Recently, HPV has been shown to be a new pivotal factor in the development of HNSCC, specifically in OPSCC ([@ref-29]; [@ref-33]). However, the role of HPV in head and neck cancers other than OPSCC remains unclear. In oral squamous cell carcinoma (OSCC), although [@ref-35] found a high incidence of p16 overexpression (especially in the oral tongue area, 36.3%), only 6% of OSCC cases were considered HPV-driven tumors. In LSCC, the exact role of HPV infection remains controversial, and the prevalence varies widely from 6.8% to 58.8%, with an average prevalence of 28% reported in a recent meta-analysis ([@ref-22]; [@ref-8]; [@ref-19]).

Several factors may contribute to the high variation in HPV prevalence. [@ref-20] suggested that a higher prevalence could be explained by a high frequency of false-positive results caused by sample contamination. With the technical advances in HPV detection, the prevalence of HPV in patients with LSCC has been quite low in recent publications. In two recent studies involving a large patient series from China and the UK, the prevalence was only 7.57% and 3.2%, respectively ([@ref-31]; [@ref-34]). Another international cross-sectional study of 3,680 head and neck cancer samples found a low HPV prevalence, except in patients with OPSCC, and only 3.5% of laryngeal cancers were HPV-positive ([@ref-5]). We also found a relatively low HPV prevalence: 13.2% of patients with LSCC in Taiwan.

Geographic differences may also contribute to the wide range of HPV infection rates in LSCC. Unlike other countries, betel quid chewing is an important threat to public health in Taiwan in addition to smoking and drinking. Patients who habitually chew betel nut were found to have a higher incidence of supraglottic cancer versus glottic cancer (52.8% *vs*. 35.8%, *p* = 0.003). This suggested that betel nut chewing is a risk factor for the development of supraglottic cancer, in addition to smoking and drinking.

In our study, HPV-16 was the major HPV type, as in other reports ([@ref-16]). No low-risk HPV types were detected in patients with LSCC in our cohort. Unlike the epidemiological signature of patients with HPV-positive OPSCC, younger patients and those with early T stage disease with extensive nodal metastasis showed no consistent characteristic findings in HPV-positive LSCC ([@ref-23]). [@ref-34] found that HPV-positive tumors were associated with supraglottic cancer, non-smokers, and non-drinkers. [@ref-12] found a higher prevalence of HPV-positive tumors in women and in patients with node-positive cancer or metastasis. [@ref-10] found that HPV-positive tumors were more likely to be poorly differentiated. However, we did not find any association of HPV status with clinical stage, nodal metastasis, secondary aerodigestive cancer, tumor subsites, or tumor differentiation ([Table 1](#table-1){ref-type="table"}). In our series, patients with HPV-positive tumors were significantly older and marginally significantly non-smokers (*p* = 0.068). This result is compatible with those of [@ref-34] and [@ref-3].

Only a few studies have reported the prognosis of HPV-positive LSCC, and these studies failed to show an improved OS ([@ref-34]; [@ref-12]; [@ref-28]). In our series, the OS may not actually reflect the survival advantage of HPV-positive LSCC tumors, since only 14 of 35 deaths were attributed to LSCC. One-third of the deaths were caused by lung cancer, COPD, or esophageal cancer. In addition, none of the patients with HPV-positive LSCC experienced treatment failure, showing 100% local/regional control. HPV-positive LSCC showed a trend toward a better 5-year DSS (100% *vs*. 84.8%, *p* = 0.1485) and a significant improvement in the local/regional control rate (100% *vs*. 75%, *p* = 0.0494). Less aggressive tumor behavior and a better response to adjuvant radiotherapy/concurrent chemoradiotherapy of HPV-positive tumors were possible causes of these clinical outcomes. [@ref-28] observed an improvement in 2-year DFS in HPV-positive laryngeal and hypopharyngeal cancer patients treated with chemoradiotherapy, but they did not specify the results for LSCC. Although previous reports have not observed a survival advantage in HPV-positive LSCC, we found that patients with HPV-positive LSCC had 100% 5-DSS and 100% local/regional control rates if they underwent primary surgery.

To the best of our knowledge, this is the first report on HPV prevalence in LSCC in Taiwan, where habitual betel nut chewing is common. A limitation of this study is that the presence of HPV DNA in LSCC does not provide sufficient evidence for HPV-induced carcinogenesis. Further biomarkers including p16 and E6/E7 mRNA should be investigated to determine oncogenic activity. However, p16 overexpression is not as reliable of a marker for LSCC as for OPSCC, since it may be triggered by other pathways ([@ref-27]). For determination of HPV-induced LSCC in clinical settings, [@ref-9] proposed that detection of HPV DNA is the first step, followed by detection of E6/E7 mRNA in positive cases. Currently, limited data on HPV mRNA in LSCC are available, and further prospective studies are required to clarify its roles in prognosis and therapeutic efficacy.

Conclusions
===========

The prevalence of HPV in patients with LSCC was only 13.2% in our series. The low prevalence of HPV infection suggests that HPV is not a major cause of LSCC. In addition to smoking and drinking, betel nut chewing increases the risk of supraglottic cancer. HPV-related tumors had no significant impact on OS, although a 100% local/regional control rate and 100% 5-year DSS were observed in the patients who underwent primary surgery to treat LSCC. However, a larger sample size is necessary to confirm our observations.
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